A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation

Annals of Surgery

Volumn 253, Issue 2, 2011, Pages 328-335

  Eric, Lutz ^a   Yeo, Charles J ^c   Lillemoe, Keith D ^d   Biedrzycki, Barbara ^a   Kobrin, Barry ^a   Herman, Joseph ^a   Sugar, Elizabeth ^b   Piantadosi, Steven ^f   Cameron, John L ^a   Solt, Sara ^a   Onners, Beth ^a   Tartakovsky, Irena ^a   Choi, Miri ^a   Sharma, Rajni ^a   Illei, Peter B ^a   Ralph H , Hruban ^a   Abrams, Ross A ^e   Le, Dung ^a   Elizabeth, Jaffee ^f,g   Laheru, Dan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A1 ANTIGEN; HLA A2 ANTIGEN; MESOTHELIN;

ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL SECRETION; CELLULAR DISTRIBUTION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EOSINOPHILIA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERPIGMENTATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; IRRADIATION; LEUKOCYTOSIS; LYMPH NODE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHILIA; NIGHT SWEAT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECALL INDURATION; SKIN ABRASION; SURVIVAL TIME; TREATMENT DURATION; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GPI-LINKED PROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES; TRANSFECTION;

EID: 79151486551     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181fd271c     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58(2):71-96.
2. Yeo, CJ, Pluth-Yeo T, Hruban R, et al. Cancer of the Pancreas. In: DeVita VT, ed. Principles and Practice of Oncology. 7th ed. Philadelphia: J.B. Lippincott Co; 2005:945-986.
3. Stockten DD, B̈uckler MW, Dervenis C, et al. Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92(8): 1372-1381.
4. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899-903.
5. Bakkevold KE, Arnesjo B, Dahl O, et al; Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and ampulla of vater-results of a controlled, prospective, randomized multicentre study. Eur J Cancer. 1993;29(5):698-6703.
6. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocrcinoma of the pancreas- 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
7. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-Fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230(6):776-784.
8. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
9. Regine WF, Winter KW, Abrams R, et al. Fluorouracil versus gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection for of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-1026.
10. Picozzi VJ, Kozarek RE, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185(5):476-480.
11. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative intent resection of pancreatic cancer. JAMA. 2007;297(3):267-277.
12. Jaffee EM, Hruban R, Biedrzycki B, et al. A novel allogeneic GM-CSF secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19(1):145-156.
13. Cao D, Maitra A, Saavedra JA, et al. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol. 2005;18(6):752-761.
14. HassanR, Laszik ZG, Lerner M, et al.Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124(6):838-845.
15. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008;7(2): 286-296.
16. Thomas AM, Santarsiero LM, Lutz ER, et al.Mesothelin-specific CD8+T cell responses provide evidence of in vivo cross priming by antigen presenting cells in vaccinated pancreatic cancer patients. J ExpMed. 2004;200(3):297-306.
17. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am. 1998;4(3):194-203.
18. Jaffee EM, Abrams RA, Cameron JL, et al. A phase I trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther. 1998;9(13): 1951-1971.
19. Lawless J. Statistical Models and Methods for Lifetime Data. John Wiley & Sons; 1982.
20. R Development Core Team; R. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2007; ISBN3-900051-07-0, http://www.R-project.org. Accessed October 15, 2010.
21. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5): 2756-2761.
22. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423-5434.